How Amorphous Solid Dispersion Improves Drug Solubility

An amorphous solid dispersion is a pharmaceutical formulation in which a poorly soluble drug is molecularly mixed into a polymer matrix, locked in a disordered, non-crystalline state that dissolves far more readily than the drug’s natural crystal form. The strategy exists because a large and growing share of drug candidates emerging from discovery pipelines barely dissolve in water, which means the body absorbs them poorly or unpredictably. By stripping away the crystal lattice and stabilizing the drug inside a polymer, ASDs can boost the amount of drug that actually reaches the bloodstream by roughly twofold or more, depending on the compound.

Why Crystalline Drugs Are a Problem

Most small-molecule drugs, when synthesized, settle into a crystalline structure. The molecules stack into a repeating lattice held together by intermolecular forces. Dissolving a crystal means breaking those forces, and for many compounds the energy cost is high enough that the drug barely dissolves in the watery environment of the gut. Poor dissolution leads to poor absorption, which leads to a drug that works beautifully in a test tube but fails in a patient. ASDs sidestep this by keeping the drug in a high-energy amorphous form, where the molecules are arranged randomly, much like a liquid frozen in place. Because there is no crystal lattice to dismantle, the drug dissolves faster and to a higher concentration than its crystalline counterpart.¹

The catch is that amorphous forms are inherently unstable. Left alone, a disordered drug wants to relax back into its lower-energy crystalline state. The polymer carrier in an ASD acts as a molecular chaperone: it limits the drug’s mobility, forms stabilizing interactions like hydrogen bonds, and raises the system’s glass transition temperature so that the drug stays “frozen” in its amorphous state at room temperature. The whole formulation strategy boils down to a race between dissolution (which needs the amorphous advantage) and recrystallization (which erases it).

The Spring-and-Parachute Effect

When an ASD hits gastrointestinal fluid, it creates a burst of dissolved drug at concentrations well above the drug’s normal solubility limit. Formulators call this the “spring” because it launches drug concentration upward rapidly. The problem is that a supersaturated solution is thermodynamically unhappy and wants to crash back down through precipitation. The polymer in the ASD, along with any added excipients, acts as a “parachute” that slows that precipitation and keeps the drug in a dissolved or finely dispersed state long enough for absorption to occur.² The interplay between the speed of supersaturation generation and the effectiveness of precipitation inhibition determines whether the formulation actually delivers more drug into the bloodstream than a simple crystalline tablet would.

Drug-Rich Nanodroplets and How They Help Absorption

Something interesting happens when an ASD dissolves at concentrations above the drug’s amorphous solubility limit: the excess drug does not simply precipitate as crystals. Instead, it phase-separates into tiny, drug-rich liquid nanodroplets suspended in the dissolution medium. For years, researchers assumed only truly dissolved (molecularly dispersed) drug could cross the gut wall. That picture has gotten more complicated. Studies using membrane-transfer experiments have shown that these drug-rich nanodroplets increase the total amount of drug that makes it across a membrane, and that the effect scales with the number of nanodroplets present.³

Work in rat intestinal perfusion models has gone further, providing evidence that drug-rich nanodroplets can be directly taken up by the epithelial cells lining the small intestine. Although the permeability of individual nanodroplets is far lower than that of dissolved drug molecules, the sheer quantity of nanodroplets can be several hundred times higher than the dissolved drug concentration, so their aggregate contribution to absorption becomes significant.⁴ Separate work with the drug albendazole confirmed that oral absorption from ASDs correlated better with the concentration at which liquid-liquid phase separation occurred than with conventional dissolution measurements, reinforcing the idea that these nanodroplets are a real and measurable absorption pathway, not just a laboratory curiosity.⁵

How ASDs Are Made

Two manufacturing methods dominate the field. Spray drying dissolves both the drug and the polymer in a volatile solvent, then atomizes the solution into a stream of heated gas. The solvent evaporates extremely fast from the tiny droplets, trapping the drug in the polymer matrix before it has any chance to crystallize.⁶ Hot-melt extrusion takes a different route: it melts the drug and polymer together under heat and shear inside a barrel, then forces the molten blend through a die. No solvent is needed, which simplifies cleanup and avoids residual-solvent concerns, but the temperatures involved can degrade sensitive drugs or polymers. Research has shown that barrel temperature and screw speed during extrusion directly affect the polymer’s molecular weight and, downstream, the drug’s release profile, so the process window can be narrow.⁷

Among approved ASD products in the United States between 2012 and 2023, spray drying accounted for about 54% of the manufacturing approaches and hot-melt extrusion for about 35%.⁸ A third approach, KinetiSol dispersing, is gaining attention as a solvent-free alternative with much shorter thermal exposure times than extrusion, making it more suitable for heat-sensitive compounds. Electrospinning, which generates nanofiber-based ASDs from a solvent, is also under investigation but remains far from commercial readiness.⁹

Choosing the Right Polymer

The polymer is arguably the most important design decision in an ASD. It determines how well the drug stays amorphous, how fast the system dissolves, and how the formulation behaves during storage. Among FDA-approved ASD products, copovidone (a copolymer of vinylpyrrolidone and vinyl acetate) is used in about 49% of cases, and hypromellose acetate succinate (HPMCAS) in about 30%.¹⁰ Their popularity reflects a combination of regulatory familiarity, processability, and track records of stabilizing diverse drugs.

What makes one polymer better than another for a given drug often comes down to the strength of hydrogen bonding between the drug and polymer molecules. Research comparing two structurally similar diabetes drugs, indapamide and glibenclamide, found that differences in their hydrogen-bonding patterns with the polymer HPMC explained why HPMC was much better at maintaining supersaturation for one drug than the other.¹¹ The implication is practical: picking a polymer without understanding how it interacts with a specific drug molecule is guesswork, and the consequences show up as stability failures or underwhelming performance.

Why Stability Is the Hardest Part

An ASD that performs beautifully on the day it is made can fail months later if the drug recrystallizes during storage. Two threats drive this instability. The first is molecular mobility at elevated temperature: if the product is stored above or near its glass transition temperature, the drug molecules gain enough freedom of movement to find each other and nucleate crystals. The second, and often more insidious, is moisture. Water absorbed from the environment acts as a plasticizer, lowering the glass transition temperature and increasing molecular mobility even at room temperature. This can trigger both recrystallization and a precursor event called amorphous-amorphous phase separation, where the drug and polymer begin to unmix into drug-rich and polymer-rich regions.¹²

Research into what protects ASDs from moisture-driven phase separation has pointed to three factors: stronger drug-polymer interactions, lower overall hygroscopicity (how much water the system absorbs), and a less hydrophobic drug molecule. Systems that check those boxes tend to resist phase separation even at high humidity, while systems with weak drug-polymer interactions and water-loving polymers are at higher risk.¹³ Packaging with desiccants and moisture-barrier films is standard practice, but it is a band-aid rather than a cure; the underlying formulation needs to be stable enough that reasonable storage conditions do not unravel it.

Detecting Phase Separation and Crystallization Early

Catching physical instability before it ruins a batch requires sensitive analytical tools, and no single technique tells the whole story. X-ray diffraction is the workhorse for detecting crystalline material in an ASD, but it is blind to the early stages of amorphous-amorphous phase separation that precede crystal formation. Thermal analysis using differential scanning calorimetry can detect glass transition shifts but struggles when the drug and polymer have overlapping thermal events. Solid-state nuclear magnetic resonance spectroscopy offers both quantitative crystallinity data and insight into how crystal quality changes under different conditions, filling gaps that the other methods miss.¹⁴

Newer imaging approaches aim to watch phase separation as it happens. Time-of-flight secondary ion mass spectrometry (ToF-SIMS) imaging can detect drug-rich clusters forming on an ASD surface within the first days of storage, well before X-ray diffraction would register anything crystalline.¹⁵ Stimulated Raman scattering microscopy has been used to track, in real time, how water penetrates an ASD film and triggers both surface and bulk phase separation, revealing that drug loading dramatically affects the pattern and speed of these events.¹⁶ These imaging methods are research tools today rather than routine quality-control instruments, but they are reshaping how scientists understand what goes wrong inside an ASD over time.

Turning ASD Powder Into a Tablet

An ASD by itself is usually a fine powder. Patients take tablets or capsules, so that powder has to be blended with fillers, disintegrants, and other excipients and compressed into a final dosage form. This step introduces its own problems. Tablets with a high proportion of ASD tend to disintegrate slowly because the hydrophilic polymer swells and gels on contact with water, forming a sticky barrier that resists break-up.¹⁷ For less potent drugs requiring larger doses, the ASD loading in a tablet can exceed 50%, and disintegration time increases steeply beyond that threshold.¹⁸ The result is a large pill that breaks apart too slowly, delaying or reducing drug release. Balancing ASD content, filler choice, disintegrant type, and compression force is an exercise in compromise, and keeping pill size manageable for the patient is a persistent headache for formulation teams working on high-dose compounds.

What Happens In Vivo

Ultimately, the value of an ASD is measured in pharmacokinetic studies: does more drug reach the bloodstream compared with the crystalline form? The evidence across multiple compounds says yes, often substantially. A dog study with the compound GDC-0334 showed that an ASD tablet delivered roughly 1.8 to 2.5 times the drug exposure of the crystalline form.¹⁹ For pretomanid, a tuberculosis drug, an ASD formulated with an enteric polymer achieved about 155% of the exposure of the crystalline reference product in fasted-state studies.²⁰

A Phase 1 clinical study comparing two ASD formulations of the pain compound ABT-102 (one made by melt extrusion, one by spray drying) against an oral solution found that both solid-dispersion tablets delivered higher peak concentrations and total exposures than the solution under fed conditions. The melt-extruded formulation showed no food effect, meaning it performed the same whether patients had eaten or not, which is a practical advantage for dosing convenience. The spray-dried version showed a modest food effect, with peak concentration and total exposure rising an estimated 11% and 17%, respectively, after a high-fat meal.²¹ Food effects are a common concern with poorly soluble drugs because fat in a meal can alter dissolution and absorption unpredictably. An ASD that eliminates or minimizes this variability simplifies both clinical development and real-world use.

Predicting Performance Before You Make a Batch

The traditional approach to ASD development involves screening many drug-polymer combinations experimentally, which is slow and material-intensive. Computational tools are increasingly used to narrow the field before anyone touches a spray dryer. Molecular dynamics simulations can estimate how well a drug and polymer mix at the molecular level, while mathematical frameworks like Hansen solubility parameters and Flory-Huggins interaction parameters offer quicker, rougher predictions of compatibility.²²

These tools are helpful but imperfect. Recent work using molecular dynamics simulations to rank polymer compatibility revealed a subtle trap: the molecular weight of the polymer itself can have a bigger effect on the calculated compatibility score than the polymer’s actual chemistry. Longer polymer chains produced lower solvation free energies, seemingly predicting better compatibility, yet that mathematical advantage did not translate into higher real-world solubility of the drug in the polymer.²³ The lesson is that computational screening can accelerate development, but it has to be validated experimentally rather than taken at face value. A simulation that says polymer A is better than polymer B might be reflecting a chain-length artifact rather than a genuine chemical affinity.

Biorelevant Testing to Forecast What Happens in a Patient

Standard dissolution testing, where you drop a tablet into a beaker and measure how much drug dissolves, often overpredicts or underpredicts ASD performance because it ignores absorption. In the body, drug that dissolves is continuously being absorbed across the gut wall, which prevents the supersaturated solution from precipitating as quickly as it does in a closed beaker. Dissolution-permeation setups attempt to mimic this by coupling a dissolution compartment with a membrane that allows drug to permeate into a second “absorptive” compartment. One such system showed good correlation between its in vitro predictions and actual clinical outcomes in patients.²⁴ This matters because it can reduce the number of expensive animal and human studies needed to identify a winning formulation.

A related approach uses a biomimetic polymer membrane and biorelevant media to evaluate not just how much drug dissolves but how much of that dissolved drug is truly “free” and available to cross a biological barrier, as opposed to being trapped in micelles or other colloidal structures that look like dissolved drug in a standard assay but do not contribute to absorption the same way.²⁵ For ASD formulators, these tools are becoming essential as the field moves away from “dissolves more, so it must work better” toward a more nuanced understanding of which dissolved species actually drive absorption.

Ternary Systems and Surfactant Additions

The classic ASD is a two-component system: drug plus polymer. Increasingly, formulators are adding a third ingredient, creating what the field calls ternary solid dispersions. That third component might be a surfactant, a second polymer, or a small-molecule additive, and the goal is usually to address a limitation of the binary system, whether that is insufficient stability, slow dissolution, or poor processability.²⁶

Surfactant-containing ASDs are a well-studied subset. When a surfactant is incorporated into an ASD of ritonavir and copovidone, drug release improves compared to the binary system. The mechanism involves two effects: the surfactant increases the miscibility of drug, polymer, and water during hydration, and it disrupts a drug-rich gel barrier that otherwise forms at the tablet surface during dissolution, slowing release. Essentially, the surfactant keeps the dissolving surface “open” so water can continue penetrating.²⁷ The trade-off is added complexity: a third component means more potential interactions, more stability variables to control, and a wider design space to characterize.

The Regulatory Landscape

ASDs have moved well past the proof-of-concept stage. Between 2012 and 2023, the FDA approved 48 drug products containing amorphous solid dispersions, encompassing 36 unique drug molecules. Antiviral and anticancer drugs make up the largest share, which tracks with the fact that many compounds in those therapeutic areas are notoriously insoluble. Tablets are the dominant dosage form, though several capsule products also exist.²⁸ Familiar commercial examples include sofosbuvir (Sovaldi) and the combination of elbasvir/grazoprevir (Zepatier) for hepatitis C, and vemurafenib (Zelboraf) for melanoma, all of which use ASD technology to make otherwise poorly absorbed drugs viable as oral medications.

From a generic-drug perspective, ASDs present a challenge. Reproducing the exact amorphous state, polymer-drug interaction, and dissolution behavior of an innovator product is harder than matching a crystalline drug’s dissolution profile. The in vitro methods described earlier, especially dissolution-permeation systems, are becoming important tools for generic developers trying to demonstrate bioequivalence without running large clinical trials for every formulation iteration. The solvent choice during spray drying, for instance, influences the phase behavior and glass transition of the resulting ASD, meaning two spray-dried products using different solvents can end up with meaningfully different physical properties even if the drug and polymer are identical.²⁹ Controlling these process-dependent variables is where a lot of the development effort and intellectual property reside.